DB
RGLS

Dmitry Balyasny’s Regulus Therapeutics RGLS Stock Holding History

Dmitry Balyasny’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,253
Closed -$69.8K – 3014
2024
Q1 		$69.8K Buy
+24,253
New +$39.6K ﹤0.01% 2509
2016
Q2 		– Sell
-130
Closed -$108K – 1398
2016
Q1 		$108K Sell
130
-16
-11% -$12.7K ﹤0.01% 1197
2015
Q4 		$153K Sell
146
-2
-1% -$2K ﹤0.01% 1128
2015
Q3 		$116K Sell
148
-209
-59% -$215K ﹤0.01% 1060
2015
Q2 		$470K Buy
+357
New +$576K ﹤0.01% 869

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Dmitry Balyasny's RGLS Position: Q2 2024 in Review

Dmitry Balyasny sold out of Regulus Therapeutics (RGLS) in Q2 2024, closing a stake of 24,253 shares — an estimated $69.8K sold.

Dmitry Balyasny first reported a position in RGLS in Q2 2015 and held it in 5 quarters. The position peaked at $470K in Q2 2015. 63 funds tracked by Wall St. Rank hold RGLS as of Q2 2024.

  • Dmitry Balyasny reported no remaining Regulus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 24,253 Regulus Therapeutics shares in Q2 2024, an estimated $69.8K.
  • Dmitry Balyasny first reported a position in Regulus Therapeutics in Q2 2015 and held it in 5 quarters.
  • Dmitry Balyasny's Regulus Therapeutics position peaked at $470K in Q2 2015.
  • 63 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.